Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick J Lupardus

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Bioorganic & Medicinal Chemistry Letters|September 18, 2013
Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitorsSharada Labadie, Kathy Barrett, Wade S Blair, et al.
The Journal of Biological Chemistry|July 31, 2013
Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viabilityBenjamin E L Lauffer, Robert Mintzer, Rina Fong, et al.
ACS Medicinal Chemistry Letters|March 19, 2020
Discovery of Potent Benzolactam IRAK4 Inhibitors with Robust in Vivo ActivityNaomi S Rajapaksa, Alberto Gobbi, Joy Drobnick, et al.
Journal of Medicinal Chemistry|May 15, 2019
Development of Potent and Selective Pyrazolopyrimidine IRAK4 InhibitorsMarian C Bryan, Joy Drobnick, Alberto Gobbi, et al.
ACS Medicinal Chemistry Letters|January 21, 2017
GluN2A-Selective Pyridopyrimidinone Series of NMDAR Positive Allosteric Modulators with an Improved <i>in Vivo</i> ProfileElisia Villemure, Matthew Volgraf, Yu Jiang, et al.
Cell Reports|December 20, 2025
An IL-12 partial agonist sustains intratumoral lymphocyte activation and detoxifies systemic IL-12 therapyIevgen Koliesnik, Michael Totagrande, Bhargavi Jayaraman, et al.
Bioorganic & Medicinal Chemistry Letters|October 31, 2012
Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2Sharada Labadie, Peter S Dragovich, Kathy Barrett, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2013
Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1Christopher A Hurley, Wade S Blair, Richard J Bull, et al.
Journal of Medicinal Chemistry|February 28, 2016
Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based DesignMatthew Volgraf, Benjamin D Sellers, Yu Jiang, et al.
Journal of Medicinal Chemistry|June 16, 2012
Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2Mark Zak, Rohan Mendonca, Mercedesz Balazs, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Bioorganic & Medicinal Chemistry Letters|September 18, 2013
Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitorsSharada Labadie, Kathy Barrett, Wade S Blair, et al.
The Journal of Biological Chemistry|July 31, 2013
Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viabilityBenjamin E L Lauffer, Robert Mintzer, Rina Fong, et al.
ACS Medicinal Chemistry Letters|March 19, 2020
Discovery of Potent Benzolactam IRAK4 Inhibitors with Robust in Vivo ActivityNaomi S Rajapaksa, Alberto Gobbi, Joy Drobnick, et al.
Journal of Medicinal Chemistry|May 15, 2019
Development of Potent and Selective Pyrazolopyrimidine IRAK4 InhibitorsMarian C Bryan, Joy Drobnick, Alberto Gobbi, et al.
ACS Medicinal Chemistry Letters|January 21, 2017
GluN2A-Selective Pyridopyrimidinone Series of NMDAR Positive Allosteric Modulators with an Improved <i>in Vivo</i> ProfileElisia Villemure, Matthew Volgraf, Yu Jiang, et al.
Cell Reports|December 20, 2025
An IL-12 partial agonist sustains intratumoral lymphocyte activation and detoxifies systemic IL-12 therapyIevgen Koliesnik, Michael Totagrande, Bhargavi Jayaraman, et al.
Bioorganic & Medicinal Chemistry Letters|October 31, 2012
Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2Sharada Labadie, Peter S Dragovich, Kathy Barrett, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2013
Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1Christopher A Hurley, Wade S Blair, Richard J Bull, et al.
Journal of Medicinal Chemistry|February 28, 2016
Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based DesignMatthew Volgraf, Benjamin D Sellers, Yu Jiang, et al.
Journal of Medicinal Chemistry|June 16, 2012
Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2Mark Zak, Rohan Mendonca, Mercedesz Balazs, et al.
Pageof 4